Key result
Xinshuitong Capsule significantly reduced mortality (24% vs 47%, P<0.05) and attenuated myocardial edema and cardiac remodeling in rats with Doxorubicin-induced chronic heart failure.
Why the study?
Although Xinshuitong Capsule has shown beneficial effects in chronic heart failure patients, its effect on doxorubicin-induced cardiotoxicity remains unclear.
Does Xinshuitong Capsule attenuate doxorubicin-induced cardiotoxicity and myocardial edema in a rat model of chronic heart failure?
RCT (n=90)
randomized
Does Xinshuitong Capsule attenuate doxorubicin-induced cardiotoxicity and myocardial edema in a rat model of chronic heart failure?
Absolute Event Rate: 24% vs 47%
p-value: p=< 0.05
Xinshuitong Capsule attenuates doxorubicin-induced cardiotoxicity, myocardial edema, and mortality in a rat model of chronic heart failure by inhibiting aquaporins 1, 4, and 7.
Authors
No takes yet. Share an insight, caveat, or question.
XST may mitigate Dox cardiotoxicity in rats; leaves open clinical translation and human efficacy.
Tan et al. (2021) conducted an RCT in Doxorubicin-induced chronic heart failure (n=90). Xinshuitong Capsule (XST) vs. Model group (untreated) and captopril-treated group was evaluated on Mortality rate (p=< 0.05). Xinshuitong Capsule significantly reduced mortality (24% vs 47%, P<0.05) and attenuated myocardial edema and cardiac remodeling in rats with Doxorubicin-induced chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: